WiDr細(xì)胞

生長狀態(tài)： 貼壁生長

器官來源： 結(jié)腸

數(shù)量： 大量

細(xì)胞形態(tài)： 上皮樣

是否是腫瘤細(xì)胞： 1

物種來源： 人

ATCC Number： CCL-218?

相關(guān)**： 大腸癌

運(yùn)輸方式： 凍存運(yùn)輸

Designations: WiDr

Depositors: P Noguchi

WiDr細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: colon

Disease: colorectal adenocarcinoma

Cellular Products: carcinoembryonic antigen (CEA) 118 ng/10 exp6 cells/10 days; Colon Specific Antigen (CSAp); transforming growth factor beta; keratin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Applications: transfection host

Receptors: WiDr細(xì)胞epidermal growth factor (EGF)

Tumorigenic: Yes

Antigen Expression: HLA A24, A32, B15, B18

DNA Profile (STR): Amelogenin: X

CSF1PO: 11,12

D13S317: 11,12

D16S539: 11,12

D5S818: 11,12

D7S820: 10

THO1: 6,9

TPOX: 8,9

vWA: 17,19

Isoenzymes: ES-D, 1

G6PD, B

PEP-D, 1

PGD, A

PGM1, 1-2

PGM3, 1-2

Gender: female

Comments: WiDr細(xì)胞Although deposited with the ATCC as a colon adenocarcinoma line established from a 78 year old female, DNA fingerprinting has shown this line to be a derivative of HT-29 (ATCC HTB-38).

The cells are negative for Colon Antigen 3 expression.

The cells are positive for keratin by immunoperoxidase staining.

The cells expressed p53 antigen (the p53 produced has a G -> A mutation resulting in Arg -> His at position 273).

Growth of WiDr cells is inhibited by tumor necrosis factor alpha (TNF alpha).

Inhibitors of dihydrofolate reductase are highly cytotoxic to WiDr cells.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:12 is recommended

Medium Renewal: Twice per week

Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.

Add fresh culture medium, aspirate and dispense into new culture flasks.

Preservation: culture medium 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003

recommended serum:ATCC 30-2020

derivative:ATCC HTB-38

References: 2150: WiDr細(xì)胞Noguchi P, et al. Characterization of WiDr: a human colon carcinoma cell line. In Vitro 15: 401-408, 1979. PubMed: 90012

21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111

22411: Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

23109: Smith SG, et al. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. 53: 5697-5706, 1993. PubMed: 8242626

23322: Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228

26052: Petricciani JC, et al. A comparison of three in vivo assays for cell tumorigenicity. Cancer Res. 34: 105-108, 1974. PubMed: 4203458

26053: Tsuboi KK, Kwong LK. Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res. 38: 3745-3750, 1978. PubMed: 698934

26054: Noguchi PD, et al. Chick embryonic skin as a rapid organ culture assay for cellular neoplasia. Science 199: 980-983, 1978. PubMed: 203036

32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

32270: Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963